Founded by Prof. Dr. Rana Sanyal and Sena Nomak, RS Research is developing novel targeted drug-delivery technology that aims to reduce the side effects of chemotherapy drugs, while increasing their effectiveness. ACT Venture Partners has backed RS Research since their first investment round in 2017. The new funding will be used to accelerate the clinical development processes of drug candidates in the company’s portfolio.
(TR) Read more about the story.
(ENG) Read more about the story.